This site uses cookies to ensure the best viewing experience for our readers.
China’s CMS Medical Signs Multi-Million Dollar Deal With Israeli Pharma Company Can-Fite

China’s CMS Medical Signs Multi-Million Dollar Deal With Israeli Pharma Company Can-Fite

New York-listed Can-Fite develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer

Amarelle Wenkert  :  2018-08-07T14:59:18..
CMS Medical Venture Investment Limited, a wholly-owned subsidiary of China Medical System Holdings Limited, has signed a licensing, development, and distribution agreement with New York-listed Israeli pharmaceutical company Can-Fite BioPharma Ltd., the companies announced Monday.

For daily updates, subscribe to our newsletter by clicking here.

Can-Fite is a developer of small molecule drugs used in the treatment of liver and inflammatory diseases and cancer. The Company’s lead drug candidate, Piclidenoson, is currently in a Phase III trial for rheumatoid arthritis and is expected to enter a Phase III trial for psoriasis by the end of the year.

Pharma (illustration). Photo: Shutterstock Pharma (illustration). Photo: Shutterstock Pharma (illustration). Photo: Shutterstock
The CMS deal will see the commercialization in China of Can-Fite’s Piclidenoson and Namodenoson, which is used in the treatment of advanced liver cancer. CMS Medical will be responsible to further develop these drugs and obtain regulatory approval in China.

CMS Medical has made an upfront payment of $2 million to Can-Fite and committed to milestone payments of up to $14 million upon achievement of certain regulatory milestones, and payments of up to $58.5 million upon the achievement of certain sales milestones. The agreement includes double-digit royalty payments on net sales.

Related stories

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS